Description
A Cdk1 inhibitor (IC50 = 20 μg/ml in PC-14 cells); induces dose-dependent G2/M arrest, inhibits DNA synthesis, and decreases Cdk1 protein expression in vitro; has antitumor effects in non-small lung, small cell lung, and prostate cancer cell lines (average IC50 = 50 μg/ml); inhibits in vitro Cdk1 phosphorylation of tau; inhibits in vivo phosphorylation of transcription factor E2F-1; increases biogenesis of the secondary metabolite lovastatin and conidiation in A. terreus,
Formal name: (2R)-2,5-dihydro-4-hydroxy-2-[[4-hydroxy-3-(3-methyl-2-buten-1-yl)phenyl]methyl]-3-(4-hydroxyphenyl)-5-oxo-2-furancarboxylic acid, methyl ester
Synonyms:
Molecular weight: 424.5
CAS: 87414-49-1
Purity: ≥95%
Formulation: A solid
Product Type|Biochemicals|Kinase Inhibitors|CDKs||Product Type|Biochemicals|Natural Products|Microbial Metabolites||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Cancer|Cell Cycle|G2/M||Research Area|Cancer|Cell Signaling||Research Area|Cancer|Transcription Factors||Research Area|Neuroscience